International Journal of Chronic Diseases / 2014 / Article / Tab 2

Research Article

The Lived Experience of Lupus Flares: Features, Triggers, and Management in an Australian Female Cohort

Table 2

Patient reported flare frequency and symptoms.

Borderline SLE
ACR 3+1
()
SLE
ACR 4+
()
All patients
()

Mean ± SDMean ± SDMean ± SD

Flare days calculated count32.9 ± 38.729.2 ± 39.029.9 ± 38.8

Number (%)Number (%)Number (%)

Flare day groups
 Any events21 (100)68 (85)89 (88.1)
 No events 12 (15)12 (11.9)
 <50 flare days17 (81)53 (66.3)70 (69.3)
 50–150 flare days4 (19.1)13 (16.3)17 (16.8)
 >150 flare days2 (2.5)2 (2)
Flare frequency since management*
 Decreased9 (42.9)54 (67.5)63 (62.4)
 Increased4 (19.1)10 (12.5)14 (13.9)
 Remained the same8 (38.1)16 (20)24 (23.8)
General health since diagnosis**
 Remained the same3 (13.6)18 (22.2)21 (20.6)
 Improved13 (59.1)38 (46.9)51 (50.0)
 Deteriorated5 (22.7)24 (29.6)29 (28.4)
Reported symptom exacerbation***
 Joint and muscle pain18 (85.7)56 (70)74 (73.3)
 Fatigue12 (57.1)54 (67.5)66 (65.4)
 Rash5 (23.8)25 (31.3)30 (29.7)
 Headaches5 (23.8)19 (23.8)24 (23.8)
 Fevers4 (19.0)11 (13.8)15 (14.9)
 Joint swelling4 (19.1)11 (13.8)15 (14.9)
 Abdomen/gastrointestinal 4 (19.1)10 (12.5)14 (13.9)
 Brain fog/cognitive clouding1 (4.8)11 (13.8)12 (11.9)
 UV sensitivity2 (9.5)9 (11.3)11 (10.9)
 Shortness of breath3 (14.3)7 (8.8)10 (9.9)
 Raynaud’s episodes increase1 (4.8)9 (11.3)10 (9.9)
 Infection3 (14.3)7 (8.8)10 (9.9)
 Chest pain1 (4.8)8 (10)9 (8.9)
 Skin dryness3 (14.3)6 (7.5)9 (8.9)
 Skin changes3 (14.3)5 (6.3)8 (7.9)
 Dizzy spells3 (14.3)5 (6.3)8 (7.9)
 Ulcers1 (4.8)6 (7.5)7 (6.9)
 Muscle weakness7 (8.8)7 (6.9)
 Alopecia1 (4.8)5 (6.3)6 (5.9)
 Sleep disturbance2 (9.5)3 (3.8)5 (5)
 Neuralgia4 (5)4 (4)
 Vision changes1 (4.8)3 (3.8)4 (4)
 Sore throat3 (14.3)1 (1.3)4 (4)
 Depression, anxiety, stress1 (4.8)2 (2.5)3 (3)
 Change of mood3 (3.8)3 (3)
 Serositis2 (2.5)2 (2)
 Anaemia 2 (2.5)2 (2)
Seizures2 (2.5)2 (2)
Anorexia2 (2.5)2 (2)

Has the number of events increased or decreased with ongoing management?
**In your opinion, since your diagnosis, has your general health improved, remained the same, or deteriorated?
***What symptoms have been exacerbated?

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.